Skin Cancer (Nonmelanoma)

Pembrolizumab Demonstrates Robust Activity in Advanced and Recurrent/Metastatic CSCC
April 15, 2021

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

Biofrontera Seeks FDA-Approval of BF-RhodoLED XL for AK
March 31, 2021

Biofrontera announces it is seeking FDA-approval for its new BF-RhodoLED XL lamp to be used in combination with topical aminolevulinic acid hydrochloride gel 10% for the treatment of actinic keratosis.

New Treatments Aim to Increase Survival Rate
February 25, 2021

Cancer staging systems for squamous cell carcinoma have helped improve dermatologists’ ability to accurately stage the cancer, according to one expert.